Biological mucosal model, evaluation method for the retention of mucosal protective agents

By constructing a biological mucosa model composed of hydrogel, lipid-containing and hydrophilic polymer layers, the problem of insufficient retention and reproducibility of mucosal protectants in existing technologies has been solved, and higher evaluation accuracy has been achieved.

CN114945467BActive Publication Date: 2024-11-29FUJIFILM CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202180009499.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-01-12
Publication Date
2024-11-29
Estimated Expiration
2041-01-12

AI Technical Summary

Technical Problem

Existing biological mucosal models are not sufficiently reproducible in evaluating the retention of oral mucosal protectants, making it difficult to accurately reflect the results of the retention evaluation of biological mucosa.

Method used

A biological mucosa model was used, consisting of a hydrogel layer, a lipid layer, and a hydrophilic polymer layer. The hydrogel layer contains polysaccharides such as agar and gellan gum, the lipid layer contains lipids and plasticizers, and the hydrophilic polymer layer contains polymers with hydrophilic groups. The layered structure simulates the structure of biological mucosa.

Benefits of technology

This improves the reproducibility of the evaluation results of the retention of mucosal protectants on the mucosa of organisms, and enables a more accurate evaluation of the retention of mucosal protectants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114945467B_ABST
    Figure CN114945467B_ABST
Patent Text Reader

Abstract

The present invention provides a living mucosa model and a method for evaluating the retention of a mucosa protective agent, which can provide highly reproducible evaluation results of the retention obtained when a mucosa protective agent such as an oral mucosa protective agent is applied to the mucosa of a living body. The living mucosa model of the present invention comprises, in order, a hydrogel layer, a lipid-containing layer disposed on the hydrogel layer and having through holes in the thickness direction and containing lipids, and a hydrophilic polymer layer disposed on the lipid-containing layer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a biological mucosal model and a method for evaluating the retainability of a mucosal protective agent. Background Art

[0002] In recent years, in order to evaluate the suitability of materials for use in living organisms, biological simulation models formed of various materials have been studied.

[0003] For example, Patent Document 1 discloses a biological simulation model using hydrogel.

[0004] Previous technical literature

[0005] Patent Literature

[0006] Patent Document 1: Japanese Patent Application Publication No. 2018-9096 Summary of the invention

[0007] Technical issues to be solved by the invention

[0008] On the other hand, in recent years, with the development of materials that adhere to and protect the mucous membrane of a living body, such as oral mucosal protective agents for oral ulcers (hereinafter, also referred to as "mucosal protective agents"), it is desired to develop a living body mucosal model for evaluating the retention of the mucosal membrane of a living body by the mucosal protective agent. If there is a living body mucosal model as described above, the retention of the mucosal protective agent can be evaluated more simply without the need to evaluate the actual mucosal membrane of the living body.

[0009] The present inventors evaluated the retention of mucosal protective agents using a living mucosal model composed of a hydrogel layer as described in Patent Document 1, and found that the evaluation correlation with the retention when applied to the living mucosa was poor. More specifically, the reproducibility of retention was insufficient, that is, when a mucosal protective agent with high retention to the living mucosa was applied to the living mucosal model, its retention was high, and when a mucosal protective agent with low retention to the living mucosa was applied to the living mucosal model, its retention was low.

[0010] The present invention has been made in view of the above-mentioned circumstances, and an object of the present invention is to provide a living mucosa model with high reproducibility of evaluation results of retention obtained when a mucosa protective agent such as an oral mucosa protective agent is applied to the living mucosa.

[0011] Furthermore, another object of the present invention is to provide a method for evaluating the retention of a mucosal protective agent.

[0012] Means for solving technical problems

[0013] The present inventors have conducted intensive studies to solve the above-mentioned problems and have completed the present invention having the following structure.

[0014] (1) A biological mucosal model, which comprises:

[0015] hydrogel layer;

[0016] a lipid-containing layer containing lipids, disposed on the hydrogel layer and having through holes along the thickness direction; and

[0017] The hydrophilic polymer layer is disposed on the lipid-containing layer.

[0018] (2) The biological mucosal model according to (1), wherein

[0019] The hydrophilic polymer layer includes a polymer having a hydrophilic group selected from the group consisting of a phosphorylcholine group, a hydroxyl group, and a carboxyl group.

[0020] (3) The biological mucosal model according to (2), wherein

[0021] The polymer having a hydrophilic group contains a repeating unit having a hydrophilic group and a repeating unit having no hydrophilic group.

[0022] (4) The biological mucosal model according to any one of (1) to (3), wherein

[0023] The hydrogel layer contains polysaccharides.

[0024] (5) The biological mucosal model according to any one of (1) to (4), wherein

[0025] The hydrogel layer comprises agar and gellan gum.

[0026] (6) The biological mucosal model according to any one of (1) to (5), wherein

[0027] The lipid-containing layer further comprises polyvinyl chloride and a plasticizer.

[0028] (7) A method for evaluating the retention of a mucosal protective agent, comprising evaluating the retention of a mucosal protective agent using the biological mucosal model described in any one of (1) to (6).

[0029] Effects of the Invention

[0030] According to the present invention, when a mucosa protective agent such as an oral mucosa protective agent is used, a living mucosa model can be provided that has high reproducibility in the evaluation results of the retention obtained when the mucosa protective agent is applied to the living mucosa.

[0031] Furthermore, according to the present invention, a method for evaluating the retainability of a mucosal protective agent can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a schematic cross-sectional view of one embodiment of the biological mucosal model of the present invention. DETAILED DESCRIPTION

[0033] In the present invention, a range expressed using "to" includes both ends of "to". For example, a range expressed by "A to B" includes A and B.

[0034] (Meth)acrylate is a general term including acrylate and methacrylate.

[0035] The characteristic point of the biological mucosal model of the present invention is that it has a laminated structure including a hydrogel layer, a lipid-containing layer having through holes, and a hydrophilic polymer layer. The biological mucosal model of the present invention simulates the structure of the mucosa of a living body and can more faithfully reproduce the evaluation results of the retention obtained when the mucosal protective agent is applied to the mucosa of a living body.

[0036] In addition, the organism may be a human or an animal other than a human (eg, a mammal). Examples of the animal other than a human include primates, rodents (mice, rats, etc.), rabbits, dogs, cats, pigs, cows, sheep, and horses.

[0037] Hereinafter, one embodiment of the biological mucosal model of the present invention will be described with reference to the drawings.

[0038] Figure 1 Schematic cross-sectional view of one embodiment of the biological mucosa model of the present invention is shown in FIG.

[0039] like Figure 1 As shown in FIG. 1 , the biological mucosal model 10 of the present invention sequentially comprises a hydrogel layer 12, a lipid-containing layer 14, and a hydrophilic polymer layer 16. The lipid-containing layer 14 is provided with a through hole 18. Figure 1 , two through holes 18 are described, but as described later, the number of through holes 18 is not particularly limited.

[0040] Hereinafter, each component will be described in detail.

[0041] <Hydrogel layer>

[0042] The hydrogel layer typically contains a hydrophilic polymer forming a network structure and water that enters the network structure. In addition to the hydrophilic polymer, any material that can form a gel using water as a solvent may be used.

[0043] Examples of the material contained in the hydrogel layer include natural polymers (eg, polysaccharides, proteins, and polyamino acids) and synthetic polymers.

[0044] More specifically, natural polymers such as agar, gelatin, agarose, xanthan gum, gellan gum, sclerotium gum, gum arabic, tragacanth gum, karaya gum, cellulose gum, tamarind gum, guar gum, locust bean gum, glucomannan, chitosan, carrageenan, quince seed, galactan, mannan, starch, dextrin, curdlan, casein, pectin, collagen, fibrin, peptide, chondroitin sulfate, hyaluronate, alginic acid, alginate and derivatives thereof, and synthetic polymers such as polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyacrylamide, polymethacrylamide and polyethylene glycol can be mentioned.

[0045] Among them, from the viewpoint of higher reproducibility between the evaluation results of the retention when the mucosal protective agent is applied to the biological mucosal model of the present invention and the evaluation results of the retention obtained when the mucosal protective agent is applied to the mucosa of the organism (hereinafter also referred to as "the viewpoint that the effect of the present invention is more excellent"), the hydrogel layer preferably contains a polysaccharide, and from the viewpoint of better adhesion between the hydrogel layer and the lipid-containing layer, it is more preferable to contain agar and gellan gum.

[0046] The water content of the hydrogel layer (the content of water relative to the total mass of the hydrogel layer) is not particularly limited, but is preferably 90% by mass or more and less than 100% by mass, and more preferably 95% by mass or more and less than 100% by mass, from the viewpoint of achieving better effects of the present invention.

[0047] The thickness of the hydrogel layer is not particularly limited, but is preferably 1 to 30 mm, more preferably 5 to 15 mm, from the viewpoint of achieving more excellent effects of the present invention.

[0048] <Lipid layer>

[0049] The lipid-containing layer includes lipids disposed on the hydrogel layer. In the lipid-containing layer, lipids are easily distributed unevenly on the surface side of the lipid-containing layer.

[0050] In addition, in this specification, the so-called lipid refers to an amphiphilic lipid or an amphiphilic substance with a structure similar thereto. Generally, a lipid has a polar hydrophilic part and a hydrophobic part consisting of a carbon chain. As the hydrophilic part, a phosphate group, an amino group, a carboxyl group, a hydroxyl group and an ionic group (e.g., a quaternary ammonium salt group) etc. can be cited.

[0051] The lipid is preferably a compound selected from the group consisting of a primary amine, a secondary amine, a tertiary amine and a quaternary ammonium salt, and more preferably a quaternary ammonium salt.

[0052] Among them, tetraalkylammonium salts are preferred as lipids.

[0053] The number of carbon atoms of the alkyl group in the tetraalkylammonium salt is not particularly limited, but from the viewpoint of more excellent effects of the present invention, the number of carbon atoms of at least one alkyl group in the tetraalkylammonium salt is preferably 5 or more, more preferably 10 or more. The upper limit is not particularly limited, but is preferably 20 or less, more preferably 15 or less.

[0054] The carbon number of all alkyl groups in the tetraalkylammonium salt is preferably 5 or more, more preferably 10 or more. The upper limit is not particularly limited, but is preferably 20 or less, more preferably 15 or less.

[0055] Examples of the lipid include tetradodecylammonium bromide, tetrahexadecylammonium bromide, tetraoctadecylammonium bromide and tetradodecylammonium chloride.

[0056] The content of the lipid in the lipid-containing layer is not particularly limited, but is preferably 1 to 10% by mass, more preferably 2 to 5% by mass, based on the total mass of the lipid-containing layer.

[0057] The lipid-containing layer may contain other components besides lipids.

[0058] The lipid-containing layer may contain a binder, and examples of the binder include polymers. Examples of the binder include plastics such as polyvinyl chloride, polyvinylidene chloride, polystyrene, polyurethane, polysulfone, polycarbonate, polyarylate, polyamide, and polyvinyl alcohol, natural resins such as lacquer, polysaccharide polymers such as agar, and gelling proteins such as gelatin (collagen).

[0059] Among them, polyvinyl chloride is preferred from the viewpoint of being easily available and being easy to adjust softening and hardening by the mixing ratio with a plasticizer described later.

[0060] The content of the binder in the lipid-containing layer is not particularly limited, but is preferably 20 to 80% by mass, more preferably 40 to 60% by mass, based on the total mass of the lipid-containing layer.

[0061] The lipid-containing layer may comprise a plasticizer.

[0062] The plasticizer is a substance that can plasticize the above-mentioned adhesive and impart flexibility.

[0063] The type of plasticizer may be any one that can plasticize the adhesive to be used. When the adhesive is a plastic as described above, the plasticizer is preferably an ester compound or an ether compound.

[0064] Examples of the plasticizer include di-n-octylphenyl phosphate, 2-nitrophenyl octyl ether, 4-nitrophenyl phenyl ether, dioctyl phosphate, dioctyl sebacate, dibutyl sebacate, and tricresyl phosphate.

[0065] The content of the plasticizer in the lipid-containing layer is not particularly limited, but is preferably 10 to 80% by mass, more preferably 20 to 70% by mass, and even more preferably 30 to 50% by mass, based on the total mass of the lipid-containing layer.

[0066] The lipid-containing layer has through holes along the thickness direction. That is, the lipid-containing layer has through holes penetrating from one surface to the other surface.

[0067] The size of the through hole is not particularly limited, but from the viewpoint of achieving better effects of the present invention, the diameter of the through hole is preferably 0.1 to 2 mm, more preferably 0.5 to 1 mm. When the opening of the through hole is not a perfect circle, the major diameter is used as the diameter.

[0068] The number of through holes is not particularly limited, but is preferably 4 to 36 per cm from the viewpoint of achieving a more excellent effect of the present invention. 2 , more preferably 9 to 25 pieces / cm 2 .

[0069] In addition, the above “pcs / cm 2 " refers to the surface (main surface) containing lipid layer per 1cm 2 The number of through holes.

[0070] The thickness of the lipid-containing layer is not particularly limited, but is preferably 0.05 to 1 mm, more preferably 0.1 to 0.5 mm, from the viewpoint of achieving more excellent effects of the present invention.

[0071] <Hydrophilic polymer layer>

[0072] The hydrophilic polymer layer is a layer disposed on the lipid-containing layer, and is a layer containing a hydrophilic polymer.

[0073] The hydrophilic polymer is a polymer having a hydrophilic group. As the hydrophilic group, from the viewpoint of achieving a more excellent effect of the present invention, a hydrophilic group selected from the group consisting of a phosphorylcholine group, a hydroxyl group, and a carboxyl group is preferred.

[0074] The phosphorylcholine group is a group represented by the following formula: * indicates a bonding position.

[0075] [Chemical formula 1]

[0076]

[0077] The hydrophilic polymer preferably has a repeating unit containing the above-mentioned hydrophilic group.

[0078] The content of the repeating unit having a hydrophilic group in the hydrophilic polymer is preferably 20 to 80 mol %, more preferably 30 to 70 mol %, based on all the repeating units in the hydrophilic polymer.

[0079] Among them, from the viewpoint of better adhesion between the hydrogel layer and the lipid-containing layer, the hydrophilic polymer preferably has a repeating unit without a hydrophilic group. As the repeating unit without a hydrophilic group, it is preferably a repeating unit having an alkyl group and not having a hydrophilic group, and more preferably an alkyl (meth)acrylate.

[0080] Examples of the monomer capable of forming a repeating unit having no hydrophilic group include methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, lauryl (meth)acrylate, stearyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, benzyl (meth)acrylate, phenoxyethyl (meth)acrylate, cyclohexyl (meth)acrylate, polypropylene glycol mono(meth)acrylate, polybutylene glycol mono(meth)acrylate, polypropylene glycol di(meth)acrylate, polybutylene glycol mono(meth)acrylate, and polypropylene glycol polyethylene glycol mono(meth)acrylate.

[0081] The content of the repeating unit having no hydrophilic group in the hydrophilic polymer is preferably 20 to 80% by mass, more preferably 30 to 70% by mass, based on all the repeating units in the hydrophilic polymer.

[0082] The weight average molecular weight of the hydrophilic polymer is not particularly limited, but is preferably 50,000 to 5,000,000, more preferably 50,000 to 1,000,000, and even more preferably 500,000 to 1,000,000.

[0083] The content of the hydrophilic polymer in the hydrophilic polymer layer is not particularly limited, but from the viewpoint of achieving a more excellent effect of the present invention, it is preferably 80% by mass or more, more preferably 90% by mass or more, relative to the total mass of the hydrophilic polymer layer. The upper limit is not particularly limited, and 100% by mass may be cited.

[0084] The hydrophilic polymer layer may contain other components in addition to the above-mentioned hydrophilic polymer.

[0085] The thickness of the hydrophilic polymer layer is not particularly limited, but is preferably 1 nm to 0.1 mm, more preferably 1 nm to 0.01 mm, from the viewpoint of achieving more excellent effects of the present invention.

[0086] <Method for producing biological mucosal model>

[0087] The method for producing the biological mucosal model is not particularly limited, and a known method can be used.

[0088] For example, a hydrogel layer, a lipid-containing layer, and a hydrophilic polymer layer may be separately prepared and laminated together to produce a biological mucosal model.

[0089] Among them, a production method having the following steps 1 to 3 is preferred from the viewpoint of more excellent productivity.

[0090] Step 1: After forming a coating film using a lipid-containing layer-forming composition, a step of providing through holes in the coating film to form a lipid-containing layer

[0091] Step 2: A step of heating and applying the hydrogel layer-forming composition to bring the coating film into contact with the lipid-containing layer to form a laminate having the hydrogel layer and the lipid-containing layer

[0092] Step 3: Step of forming a hydrophilic polymer layer by applying a hydrophilic polymer layer-forming composition onto the lipid-containing layer in the laminate

[0093] Hereinafter, each step will be described in detail.

[0094] (Process 1)

[0095] Step 1 is a step of forming a coating film using the lipid-containing layer-forming composition and then providing through-holes in the coating film to form a lipid-containing layer.

[0096] The lipid-containing layer-forming composition contains at least lipids. In addition, the lipid-containing layer-forming composition may contain components that can be contained in the lipid-containing layer (for example, a binder and a plasticizer).

[0097] Furthermore, the lipid-containing layer-forming composition may contain a solvent. Examples of the solvent include water and organic solvents.

[0098] Examples of a method for forming a coating film using the lipid-containing layer-forming composition include a method of applying the lipid-containing layer-forming composition on a predetermined substrate. Examples of the coating method include known methods.

[0099] Next, through-holes are provided in the obtained coating film to form a lipid-containing layer. The method for forming the through-holes is not particularly limited, and a method of forming the through-holes by pressing a sword on the coating film can be mentioned.

[0100] After the lipid-containing layer having through-holes is formed, the obtained lipid-containing layer may be brought into contact with an aqueous solution containing a salt such as an aqueous potassium chloride solution, if necessary.

[0101] (Process 2)

[0102] Step 2 is a step of applying the hydrogel layer-forming composition while heating it so that the coating film comes into contact with the lipid-containing layer to form a laminate having the hydrogel layer and the lipid-containing layer.

[0103] The hydrogel layer-forming composition contains components that form the above-mentioned hydrogel layer.

[0104] Furthermore, the hydrogel layer-forming composition may contain a solvent. As the solvent, water is generally contained. In addition, an organic solvent may be further used.

[0105] The temperature at which the hydrogel layer-forming composition is heated is not particularly limited, and an optimal temperature is selected depending on the material used, but is generally 70 to 100°C.

[0106] As a method of applying the heated hydrogel layer-forming composition, a known method may be mentioned.

[0107] Next, the coating film of the hydrogel layer-forming composition is brought into contact with the lipid-containing layer to form a laminate having the hydrogel layer and the lipid-containing layer.

[0108] When the coating film is brought into contact with the lipid-containing layer, it is preferred that the coating film be brought into contact with the lipid-containing layer before the coating film formed by applying the heated hydrogel layer-forming composition is cooled to room temperature.

[0109] (Process 3)

[0110] Step 3 is a step of coating a hydrophilic polymer layer-forming composition on the lipid-containing layer in the laminate to form a hydrophilic polymer layer.

[0111] The hydrophilic polymer layer-forming composition contains components for forming the hydrophilic polymer layer.

[0112] Furthermore, the hydrophilic polymer layer-forming composition may contain a solvent. Examples of the solvent include water and organic solvents.

[0113] As a method of applying the hydrophilic polymer layer-forming composition, a known method may be mentioned.

[0114] <Application>

[0115] The biological mucosal model of the present invention can be applied to various purposes.

[0116] In particular, it is preferably used to evaluate the retention of a mucosal protective agent. More specifically, the retention of a mucosal protective agent can be evaluated by attaching the mucosal protective agent to the living mucosal model of the present invention, rather than by attaching the mucosal protective agent to a living body and evaluating its retention.

[0117] The mucosal protective agent is not particularly limited, and examples thereof include oral mucosal protective agents, gastric mucosal protective agents, rectal mucosal protective agents, and nasal mucosal protective agents. Among them, the biological mucosal model of the present invention is suitable for evaluating the retention of oral mucosal protective agents.

[0118] The method for evaluating the retention of the mucosal protective agent using the biological mucosal model of the present invention is not particularly limited, and examples thereof include a method in which the mucosal protective agent is attached to the biological mucosal model and its retention is evaluated. When evaluating the retention, a shaking treatment or the like may be performed as necessary.

[0119] Example

[0120] <Example 1>

[0121] A solution prepared by dissolving tetra(dodecyl)ammonium bromide (manufactured by ALDRICH) (50 mg), polyvinyl chloride (manufactured by FUJIFILM Wako Pure Chemical Corporation) (800 mg) and di-n-octylphenyl phosphate (manufactured by ALDRICH) (0.6 mL) in tetrahydrofuran (manufactured by FUJIFILM Wako Pure Chemical Corporation) (10 cc) was dried at room temperature in a petri dish to obtain a lipid-containing layer (thickness: 200 μm).

[0122] In the obtained lipid-containing layer, 16 cells / cm 2 The through-hole had a diameter of 1 mm, and the obtained lipid-containing layer was immersed in a potassium chloride aqueous solution (concentration: 10 mmol / L) for one minute.

[0123] Next, agar (Kari Korikan, Ina Food Industry Co., Ltd.) (0.5 g) and gellan gum (Kelcogell HM; DSP Gokyo Food & Chemicals) (0.1 g) were added to distilled water (49.4 g) while stirring with a stirrer, and the obtained solution was heated to 90° C. and heated until the components were dissolved. The obtained solution was poured into a culture dish, and the lipid-containing layer having the above-mentioned through holes was attached to the coating film before the coating film in the culture dish was cooled, thereby obtaining a laminate having a hydrogel layer and a lipid-containing layer. The water content of the hydrogel layer was 99% by mass, and the thickness of the hydrogel layer was 6 mm.

[0124] Next, after scraping off the portion of the hydrogel layer that had spread to the outside of the lipid-containing layer, a 2 mass % ethanol solution of MPC (2-methacryloyloxyethyl phosphorylcholine) polymer (LIPIDURE (registered trademark)-CM5206, manufactured by NOFCORPORATION) was sprayed on the surface of the lipid-containing layer to form a hydrophilic polymer layer, thereby producing a biological mucosal model having a hydrogel layer, a lipid-containing layer and a hydrophilic polymer layer in sequence.

[0125] In addition, the MPC polymer contains a repeating unit having a phosphorylcholine group and a repeating unit having no hydrophilic group.

[0126] <Example 2>

[0127] A biological mucosal model was prepared according to the same procedure as in Example 1 except that gellan gum was not used.

[0128] <Example 3>

[0129] According to the same procedure as in Example 1, a laminate having a hydrogel layer and a lipid-containing layer was obtained.

[0130] Next, the surface of the lipid-containing layer was covered with a 1 mass % methanol solution of benzophenone, and after standing for 30 seconds, the methanol solution was removed and dried naturally. Then, the obtained laminate was immersed in a 0.5 M MPC aqueous solution and irradiated with ultraviolet light (wavelength 365 nm, 20 mW / cm 2 , 3 hours), thereby obtaining a hydrophilic polymer layer as an MPC grafted layer on the lipid-containing layer.

[0131] In addition, the polymer in the hydrophilic polymer layer is composed of a repeating unit having a phosphorylcholine group and does not have a repeating unit having no hydrophilic group.

[0132] <Example 4>

[0133] A biological mucosal model was prepared according to the same procedure as in Example 1 except that gelatin was used instead of agar and gellan gum.

[0134] <Comparative Example 1>

[0135] Agar (Kari Korikan, Ina Food Industry Co., Ltd.) (0.5 g) and gellan gum (Kelcogell HM; DSP Gokyo Food & Chemicals) (0.1 g) were added to distilled water (49.4 g) while stirring with a stirrer, and the resulting solution was heated to 90° C. and heated until the components were dissolved. The resulting solution was poured into a petri dish to obtain a hydrogel layer.

[0136] The obtained hydrogel layer was used as a biological mucosal model.

[0137] <Comparative Example 2>

[0138] A laminate composed of a hydrogel layer and a lipid-containing layer was obtained by the same procedure as in Example 1 except that the hydrophilic polymer layer was not formed, and used as a biological mucosal model.

[0139] <Comparative Example 3>

[0140] After forming the hydrogel layer according to the steps of Comparative Example 1, a 2 mass % ethanol solution of MPC polymer (LIPIDURE (registered trademark)-CM5206, manufactured by NOF CORPORATION) was sprayed on the hydrogel layer to form a hydrophilic polymer layer, thereby preparing a biological mucosal model consisting of a hydrogel layer and a hydrophilic polymer layer.

[0141] <Comparative Example 4>

[0142] A lipid-containing layer was obtained by the same procedure as in Example 1. A 2 mass % ethanol solution of MPC polymer (LIPIDURE (registered trademark)-CM5206, manufactured by NOF CORPORATION) was sprayed on the obtained lipid-containing layer to form a hydrophilic polymer layer, and a biological mucosal model consisting of the lipid-containing layer and the hydrophilic polymer layer was prepared.

[0143] <Comparative Example 5>

[0144] A lipid-containing layer was obtained according to the same procedure as in Example 1 and used as a biological mucosal model.

[0145] <Comparative Example 6>

[0146] A biological mucosal model was prepared according to the same procedure as in Example 1, except that no through-holes were provided in the lipid-containing layer.

[0147] <Evaluation>

[0148] (Evaluation of human mucosal adhesion reproducibility)

[0149] The following evaluation was performed using the biological mucosal models produced in Examples and Comparative Examples. The case where all of the following requirements 1 to 3 were satisfied was rated as reproducibility "A", and the case where none of the requirements were satisfied was rated as reproducibility "B".

[0150] Necessary condition 1: Therapeutic drugs that can adhere to the human oral mucosa (Taisho Pharmaceutical Oral Ulcer Quick Care Ointment (Taisho Pharmaceutical Co., Ltd.), Traflu Ointment (DAIICHI SANKYO COMPANY, LIMITED), Soleia Pharma, Corninger Oral Ointment and ORTEXER Ointment) are respectively applied on the biological mucosal model to form a coating film (size: 1 cmΦ, thickness: 500 μm), and evaluated according to the steps described later (retention test). The retention is "A".

[0151] Necessary condition 2: After applying a 5% by mass aqueous solution of sodium alginate on the biological mucosal model, a 2% by mass aqueous solution of lactic acid Alaq is further applied on the coating to form a gelled coating (size: 1 cmΦ, thickness: 500 μm) on the biological mucosal model. The retention is evaluated according to the steps described later (retention test), and the retention is "A".

[0152] Necessary condition 3: After applying a 2% by mass aqueous solution of sodium alginate on the biological mucosal model, a 2% by mass aqueous solution of lactic acid Alaq is further applied on the coating to form a gelled coating (size: 1 cmΦ, thickness: 500 μm) on the biological mucosal model. The retention is evaluated according to the steps described later (retention test) and the retention is "B".

[0153] (Retention test)

[0154] After spraying artificial saliva (Saliveht) on the biological mucosal model equipped with the coating, let it stand for 1 minute. Then, the biological mucosal model sprayed with artificial saliva is placed in a culture dish and filled with artificial saliva (Saliveht) until the biological mucosal model is immersed. The culture dish is placed in a constant temperature oscillator (AS ONE small oscillating thermostat 1-6142-01) at 37°C and oscillated at a medium speed (scale 5). In this test, the time until the coating is peeled off from the biological mucosal model is measured, and the situation in which the coating is not peeled off within 10 minutes is evaluated as retention "A", and the situation in which the coating is peeled off within 10 minutes is evaluated as retention "B".

[0155] (Adhesion Evaluation)

[0156] After artificial saliva (Saliveht) was sprayed on the obtained biological mucosal model, it was left to stand for 1 minute. Then, the biological mucosal model sprayed with artificial saliva was placed in a culture dish and filled with artificial saliva (Saliveht) until the biological mucosal model was immersed. The culture dish was placed in a constant temperature oscillator (AS ONE small oscillating thermostat 1-6142-01) at 37°C and oscillated at a medium speed (scale 5).

[0157] Between the hydrogel layer and the lipid-containing layer, the case where no peeling occurred for more than 6 hours was set as "A", the case where peeling occurred for more than 3 hours and less than 6 hours was set as "B", the case where peeling occurred for more than 1 hour and less than 3 hours was set as "C", and the case where peeling occurred in less than 1 hour was set as "D".

[0158] In Table 1, the column "Hydrogel layer" indicates the material used, and the case where no hydrogel layer was used is indicated as "-". In addition, "GG" indicates gellan gum.

[0159] In Table 1, in the column of "lipid-containing layer", when a lipid-containing layer was used, it was set as "yes", when a lipid-containing layer was not used, it was set as "-", and when a lipid-containing layer without through-holes was used, it was set as "no*".

[0160] In Table 1, in the "Hydrophilic polymer layer" column, "A" indicates when a hydrophilic polymer layer was formed using an MPC polymer (LIPIDURE (registered trademark)-CM5206, manufactured by NOF CORPORATION), "B" indicates when an MPC graft layer was formed, and "-" indicates when no hydrophilic polymer layer was used.

[0161] In Table 1, in the column “Adhesion Evaluation”, “-” means that no evaluation was performed.

[0162] [Table 1]

[0163]

[0164] As shown in Table 1, the biological mucosal model of the present invention showed the expected effect.

[0165] Among them, from the comparison between Examples 1, 2 and 4, it was confirmed that when the hydrogel layer contained agar and gellan gum, the adhesion was more excellent.

[0166] Furthermore, from the comparison between Examples 1 and 3, it was confirmed that the adhesion was more excellent when the hydrophilic polymer layer contained a polymer containing a repeating unit having a hydrophilic group and a repeating unit having no hydrophilic group.

[0167] In Comparative Example 1, Corninger Oral Ointment, ORTEXER Ointment, and Ipsool were not adhered.

[0168] In Comparative Example 2, Ipsul was not adhered.

[0169] In Comparative Example 3, Corninger Oral Ointment, ORTEXER Ointment, and Ipsool were not adhered.

[0170] In Comparative Examples 4 to 6, Taisho Pharmaceutical Oral Ulcer Quick Care Ointment, Traflu Ointment, and Ipsool were not adhered.

[0171] Explanation of symbols

[0172] 10-biological mucosal model, 12-hydrogel layer, 14-lipid-containing layer, 16-hydrophilic polymer layer, 18-through hole.

Claims

1. A biological mucosal model, which comprises: hydrogel layer; a lipid-containing layer containing lipids, disposed on the hydrogel layer and having through holes along the thickness direction; and a hydrophilic polymer layer disposed on the lipid-containing layer, The lipid comprises a hydrophilic part having polarity and a hydrophobic part consisting of a carbon chain, and the hydrophilic part is a quaternary ammonium salt group.

2. The biological mucosal model according to claim 1, wherein: The hydrophilic polymer layer includes a polymer having a hydrophilic group selected from the group consisting of a phosphorylcholine group, a hydroxyl group, and a carboxyl group.

3. The biological mucosal model according to claim 2, wherein: The polymer having a hydrophilic group contains a repeating unit having a hydrophilic group and a repeating unit having no hydrophilic group.

4. The biological mucosal model according to any one of claims 1 to 3, wherein The hydrogel layer contains polysaccharides.

5. The biological mucosal model according to any one of claims 1 to 3, wherein The hydrogel layer comprises agar and gellan gum.

6. The biological mucosal model according to any one of claims 1 to 3, wherein The lipid-containing layer further comprises polyvinyl chloride and a plasticizer. 7 . A method for evaluating the retention of a mucosal protective agent, comprising evaluating the retention of a mucosal protective agent using the biological mucosal model according to claim 1 .

Citation Information

Patent Citations

  • Hydrogel and method for producing hydrogel

    JP2018009096A

  • Intraoral covering material

    JP2014226403A

  • Mucousa membrane adhesive formulations including drugs by irradiation and preparation method thereof

    KR1020100030324A